|
Name |
(22E,24R)-ergosta-5alpha,6alpha-epoxide-8,22-diene-3beta,7alpha-diol
|
Molecular Formula | C28H44O3 | |
IUPAC Name* |
(2R,5S,7R,9S,10S,12R,15R,16R)-15-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-2,16-dimethyl-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadec-1(11)-ene-5,10-diol
|
|
SMILES |
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3=C2[C@@H]([C@H]4[C@@]5([C@@]3(CC[C@@H](C5)O)C)O4)O)C
|
|
InChI |
InChI=1S/C28H44O3/c1-16(2)17(3)7-8-18(4)20-9-10-21-23-22(12-13-26(20,21)5)27(6)14-11-19(29)15-28(27)25(31-28)24(23)30/h7-8,16-21,24-25,29-30H,9-15H2,1-6H3/b8-7+/t17-,18+,19-,20+,21-,24-,25-,26+,27+,28-/m0/s1
|
|
InChIKey |
PCIZFQVDNDHRPP-WOIVZMLFSA-N
|
|
Synonyms |
(22E,24R)-ergosta-5alpha,6alpha-epoxide-8,22-diene-3beta,7alpha-diol; 5alpha,6alpha-epoxyergosta-8,22-diene-3beta,7alpha-diol; CHEBI:70339; DTXSID601275129; Q27138680; (22E)-5alpha,6alpha-Epoxyergosta-8,22-diene-3beta,7alpha-diol; 5alpha,6alpha-epoxy-(22e)-ergosta-8,22-dien-3beta,7alpha-diol; (3beta,5alpha,6alpha,7alpha,22E)-5,6-epoxyergosta-8,22-diene-3,7-diol; (2R,5S,7R,9S,10S,12R,15R,16R)-15-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-2,16-dimethyl-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadec-1(11)-ene-5,10-diol; 16250-61-6
|
|
CAS | 16250-61-6 | |
PubChem CID | 12019948 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 428.6 | ALogp: | 5.1 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 53.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 31 | QED Weighted: | 0.439 |
Caco-2 Permeability: | -4.865 | MDCK Permeability: | 0.00003290 |
Pgp-inhibitor: | 0.022 | Pgp-substrate: | 0.957 |
Human Intestinal Absorption (HIA): | 0.013 | 20% Bioavailability (F20%): | 0.767 |
30% Bioavailability (F30%): | 0.57 |
Blood-Brain-Barrier Penetration (BBB): | 0.047 | Plasma Protein Binding (PPB): | 86.32% |
Volume Distribution (VD): | 1.148 | Fu: | 1.85% |
CYP1A2-inhibitor: | 0.032 | CYP1A2-substrate: | 0.751 |
CYP2C19-inhibitor: | 0.056 | CYP2C19-substrate: | 0.941 |
CYP2C9-inhibitor: | 0.256 | CYP2C9-substrate: | 0.063 |
CYP2D6-inhibitor: | 0.011 | CYP2D6-substrate: | 0.175 |
CYP3A4-inhibitor: | 0.812 | CYP3A4-substrate: | 0.871 |
Clearance (CL): | 3.074 | Half-life (T1/2): | 0.134 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.152 |
Drug-inuced Liver Injury (DILI): | 0.037 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.777 | Maximum Recommended Daily Dose: | 0.945 |
Skin Sensitization: | 0.039 | Carcinogencity: | 0.005 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.041 |
Respiratory Toxicity: | 0.957 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003121 | 0.631 | D0G8OC | 0.500 | ||||
ENC006034 | 0.631 | D0G5CF | 0.491 | ||||
ENC004757 | 0.594 | D06JPB | 0.473 | ||||
ENC005438 | 0.594 | D0N1TP | 0.392 | ||||
ENC001984 | 0.594 | D01QUS | 0.366 | ||||
ENC004804 | 0.594 | D08SVH | 0.347 | ||||
ENC006033 | 0.575 | D0Y7LD | 0.333 | ||||
ENC005610 | 0.555 | D0K5WS | 0.315 | ||||
ENC004864 | 0.555 | D0T2PL | 0.295 | ||||
ENC006035 | 0.555 | D05BTM | 0.295 |